CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

被引：85

作者：

Kajinami, K

Brousseau, ME

Ordovas, JM

Schaefer, EJ

机构：

[1] Kanazawa Med Univ, Dept Cardiol, Uchinada, Ishikawa 9200293, Japan

[2] Tufts Univ, New England Med Ctr, Lipid Res Lab, Div Endocrinol Metab & Mol Biol, Boston, MA 02111 USA

[3] Tufts Univ, USDA, Human Nutr Res Ctr Aging, Lipid Metab Lab, Boston, MA 02111 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 01期

关键词：

D O I：

10.1016/j.amjcard.2003.08.078

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To test whether genetic variation in the CYP system may influence the statin response, a promoter (A290G) and 2 nonsynonymous polymorphisms (F189S and M445T) in the CYP3A4 gene locus were examined in 340 hypercholesterolemic patients who were treated with atorvastatin 10 mg. The A-290G variant allele Was significantly associated with higher levels of post-treatment low-density lipoprotein cholesterol, whereas the M445T variant was associated with lower levels at low-density lipoprotein cholesterol before and after treatment. (C) 2003 by Excerpta Medica, Inc.

引用

收藏

页码：104 / 107

页数：4

相关论文

共 20 条

[1] Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 - Response [J].

Amirimani, B ;

Walker, AH ;

Weber, BL ;

Rebbeck, TR .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1588-1590

[2] Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [J].

Ando, Y ;

Tateishi, T ;

Sekido, Y ;

Yamamoto, T ;

Satoh, T ;

Hasegawa, Y ;

Kobayashi, S ;

Katsumata, Y ;

Shimokata, K ;

Saito, H .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1587-1588

[3] Safety considerations for statins [J].

Bolego, C ;

Baetta, R ;

Bellosta, S ;

Corsini, A ;

Paoletti, R .

CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (06) :637-644

[4] Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors -: The role of metabolism -: Monograph for physicians [J].

Bottorff, M .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2273-2280

[5]

Cavalli SA, 2001, CLIN CHEM, V47, P348

[6] New insights into the pharmacodynamic and pharmacokinetic properties of statins [J].

Corsini, A ;

Bellosta, S ;

Baetta, R ;

Fumagalli, R ;

Paoletti, R ;

Bernini, F .

PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :413-428

[7] Comparison of one-year efficacy and safety of Atorvastatin versus Lovastatin in primary hypercholesterolemia [J].

Davidson, M ;

McKenney, J ;

Stein, E ;

Schrott, H ;

BakkerArkema, R ;

Fayyad, R ;

Black, D .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (11) :1475-1481

[8] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].

Evans, WE ;

McLeod, HL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549

[9] Association of CYP3A4 genotype with treatment-related leukemia [J].

Felix, CA ;

Walker, AH ;

Lange, BJ ;

Williams, TM ;

Winick, NJ ;

Cheung, NKV ;

Lovett, BD ;

Nowell, PC ;

Blair, IA ;

Rebbeck, TR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13176-13181

[10] Mutation analysis of the human CYP3A4 gene 5′ regulatory region:: population screening using non-radioactive SSCP [J].

Hamzeiy, H ;

Vahdati-Mashhadian, N ;

Edwards, HJ ;

Goldfarb, PS .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 500 (1-2) :103-110